Status:
COMPLETED
Miltefosine (Long Course) for Bolivian Mucosal Leishmaniasis
Lead Sponsor:
AB Foundation
Conditions:
Leishmaniasis
Eligibility:
All Genders
12-80 years
Phase:
PHASE1
PHASE2
Brief Summary
Miltefosine (longer course) will be used to try to improve the cure rate of mucosal leishmaniasis
Detailed Description
Miltefosine (42 days) will be used to try to improve upon the cure rate with 28 days of drug for bolivian mucosal leishmaniasisi
Eligibility Criteria
Inclusion
- Mucosal leishmaniasis
Exclusion
- No comcomitant disease as judged by laboratory and clinical parameters
Key Trial Info
Start Date :
April 1 2005
Trial Type :
INTERVENTIONAL
End Date :
December 1 2007
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT00373568
Start Date
April 1 2005
End Date
December 1 2007
Last Update
June 2 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Palos Blancos
Palos Blancos, Bolivia